Detalhe da pesquisa
1.
IAPs and RIPK1 mediate LPS-induced cytokine production in healthy subjects and Crohn's disease.
Clin Exp Immunol
; 215(3): 291-301, 2024 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37583360
2.
Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study.
J Autoimmun
; 118: 102613, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33592545
3.
Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature.
Scand J Gastroenterol
; 56(1): 53-58, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33264569
4.
Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.
Scand J Gastroenterol
; 56(9): 1040-1048, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34224299
5.
Asymptomatic Carriers Contribute to Nosocomial Clostridium difficile Infection: A Cohort Study of 4508 Patients.
Gastroenterology
; 152(5): 1031-1041.e2, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28063955
6.
Crohn's Disease With Progressive Renal Impairment.
Gastroenterology
; 158(1): 58-59, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31563621
7.
Cellular inhibitor of apoptosis protein 2 controls human colonic epithelial restitution, migration, and Rac1 activation.
Am J Physiol Gastrointest Liver Physiol
; 308(2): G92-9, 2015 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25394657
8.
Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond.
Cell Mol Life Sci
; 70(18): 3391-404, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23275943
9.
Biologics and targeted synthetic medicines for ulcerative colitis and Crohn's disease.
Ugeskr Laeger
; 186(18)2024 Apr 29.
Artigo
em Da
| MEDLINE | ID: mdl-38704716
10.
Intestinal ultrasound in inflammatory bowel disease.
Ugeskr Laeger
; 186(6)2024 02 05.
Artigo
em Da
| MEDLINE | ID: mdl-38327204
11.
Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease.
Aliment Pharmacol Ther
; 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38863153
12.
Serum Extracellular Matrix Molecules and Their Fragments as Biomarkers of Inflammation and Fibrosis in Inflammatory Bowel Diseases - A Systematic Review.
J Crohns Colitis
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38758527
13.
Effects of prednisolone tapering on effectiveness of infliximab in patients with ulcerative colitis: data from a retrospective cohort.
BMJ Open Gastroenterol
; 11(1)2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38719549
14.
Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases.
J Crohns Colitis
; 17(7): 1139-1153, 2023 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36682029
15.
Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
EClinicalMedicine
; 57: 101866, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36864986
16.
Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
Scand J Gastroenterol
; 47(5): 518-27, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22375898
17.
Biological treatment of Crohn's disease.
Dig Dis
; 30 Suppl 3: 121-33, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23295703
18.
Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis.
Inflamm Bowel Dis
; 28(11): 1756-1765, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35134921
19.
Lipidomic Trajectories Characterize Delayed Mucosal Wound Healing in Quiescent Ulcerative Colitis and Identify Potential Novel Therapeutic Targets.
Int J Biol Sci
; 18(5): 1813-1828, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35342362
20.
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis.
Dig Liver Dis
; 54(9): 1168-1178, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903497